key: cord-0740550-u7hozydd
authors: Subhadra, Bobban; Agrawal, Ragini; Pal, Virender Kumar; Chenine, Agnes-Laurence; Mattathil, Jeffy George; Singh, Amit
title: Significant Broad Spectrum Antiviral activity of Bi121 Against Different Variants of SARS-CoV-2
date: 2022-02-01
journal: bioRxiv
DOI: 10.1101/2022.01.29.477140
sha: 36549295f7b3179f7f55f4e9bee6b398ac0495ee
doc_id: 740550
cord_uid: u7hozydd

The SARS-CoV-2 pandemic infected 343 million people with over 5.59 million deaths. New mutated lineages of SARS-CoV-2 such as Omicron are evolving faster. Broad-spectrum viral inhibitors that block the initial stage of infection by reducing virus proliferation and disease severity is an unmet global medical need. We studied Bi121, a standardized polyphenolic-rich compound isolated from Pelargonium sidoides, against recombinant Vesicular Stomatitis Virus (rVSV)-pseudotyped SARS-CoV-2S (spike) that represent mutations in the spike protein of six different variants of SARS-CoV-2. Bi121 was effective in neutralizing all six rVSV-ΔG-SARS-CoV-2S variants expressing different mutations. The antiviral activity of Bi121 was then assessed against three variants of SARS-CoV-2 (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta)) using RT-qPCR and plaque assays in two different cell lines (Vero cells and HEK-ACE2). Bi121 showed significant activity toward all the three variants tested, suggesting a broad-spectrum activity.

The SARS-CoV-2 pandemic infected 343 million people with over 5.59 million deaths, markedly affecting human life and existence (1). In the US alone, over 883,903 deaths have been reported as of January 24, 2022 (2). Since its first report, several SARS-CoV-2 lineages evolved in the last 24 to 30 months (3) ; currently, the Omicron variant is dominant around the world, but researchers are monitoring other variants of concern, including the recently discovered variant of Omicron which was reported in Denmark. Evolutionary viral mutations in spike and other proteins in highly evolved lineages may warrant survival benefits to the virus to thwart the human immune system (4) . Omicron variant carries 46 high prevalence mutations specific to Omicron; Twenty-three of these are localized within the spike (S) protein and the rest localized to the other three viral structural proteins of the virus (5) .

PAXLOVID, in combination with ritonavir, developed by Pfizer, was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with SARS-CoV-2 (6). Because of the prolific nature of viral infectivity and evolutionary pressure from vaccine-induced adaptive immune response and prospective antiviral treatments, there is a high probability of the emergence of more infectious SARS-CoV-2 variants with potential drug resistance (7) . This suggests the need for antivirals with broad-spectrum neutralization activity towards various lineages of existing and future SARS-CoV-2 variants. Several single compound antivirals have shown to be effective against SARS-CoV-2 in preclinical studies and are in clinical development. However, these single molecule-single targetbased approaches may be challenging in rapidly evolving virus strains of SARS-CoV-2. There is a lack of research on broad-spectrum natural compounds that have proven effective in inhibiting coronavirus growth and replication. Many successful drug products are derived from medicinal herbs and then re-engineered to produce the active compound using synthetic chemistry. A broadspectrum viral inhibitor that targeting s various lineages of SARS-CoV-2 by blocking the initial stage of infection, including virus uptake and proliferation, may reduce the infectious viral load and, thereby, disease severity in patients.

We have studied Bi121, an aqueous polyphenolic-rich fraction from Pelargonium sidoides (PS). The aqueous ethanolic PS extract has been used as a traditional medicine for the treatment of various ailments for over a century (8) . A proprietary extract from PS roots known as EPs7630 or Umckaloabo has been evaluated in numerous clinical trials for safety and alleviation of symptoms associated with acute bronchitis and is licensed in Germany as a medicine for the treatment of upper respiratory tract infections (9) . PS extract contains numerous metabolites and was reported to inhibit viruses associated with respiratory diseases like influenza viruses (10-13), HIV (14) , and herpes virus (15) . Very recently, EPs7630 was shown to have activity against SARS-CoV-2 (16).

More than 30 clinical trials have been conducted with EPs7630 over the last 25 years (total study population > 10,500) in the treatment of acute respiratory tract infections. PS extract has excellent safety and tolerability in human clinical studies (17) . This corroborates the safety of Pelargonium-based actives for human applications. Here we investigated the antiviral activity of Bi121 against several strains of SARS-CoV2. The data provide insight into the broad-spectrum antiviral activity of Bi121 against several SARS-CoV2 strains.

Crude PS extracts were generated from dried plant roots of PS sourced from South Africa. Roots were ground with a ball mill and 100 g powdered roots were stirred in 600 ml water (ddH2O) for Misonix Inc), and the mixture was centrifuged to get a clear aqueous extract. All PS extract stock solutions were sterilized by filtration and stored at -20ºC until used for preliminary functional assays or polyphenolic enrichment.

For polyphenolic enrichment, aqueous PS extract was thoroughly mixed with polyvinylpyrrolidone (PVPP, Sigma-Aldrich); polyphenols were allowed to adsorb to PVPP at room temperature for 20 m. The mixture was filtered and washed three times with ddH2O.

Polyphenols was eluted three times each with 0.5 ml 0.5 N NaOH.

We first studied the activity of Bi121 against recombinant Vesicular Stomatitis Virus 1A) and 999.6 ( Figure. 1D) , respectively. This preliminary screening showed the broad-spectrum neutralizing ability of Bi121 to rVSV-ΔG-SARS-CoV-2 with various spike protein mutations.

To test the antiviral activity of Bi121 against SARS-CoV-2, Biom Pharmaceuticals partnered with antiviral activity of Bi121 was assessed against three variants of SARS-CoV-2 using RT-qPCR, plaque assay, and TCID50 estimation in two different cell lines (Vero E6 cells and HEK-ACE2).

The three SARS-COV-2 variants tested were: USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta).

As shown in Figure. 2, Bi121 showed significant activity towards all the three SARS-CoV-2 variants tested in two cell lines. In Vero E6 and HEK-ACE2 cells, Bi121 at 1:40 dilution significantly reduced viral replication (4-5 log reduction) compared to untreated by RT-qPCR, plaque assays, and TCID50 estimation for USA-WA1/2020 and Hongkong/VM20001061/2020 strains ( Figure. 2) . Similarly, Bi121 inhibited B.1.167.2 (Delta) replication in Vero E6 and HEK-ACE2 cells by 4-5 log using RT-qPCR and TCID50 assay and by 2-3 log using plaque assay ( Figure. 2).

The 

To further understand the antiviral activities of Bi121, we fractionated the polyphenol-rich fractions (F2, F3, F5) using mass spectroscopy is underway.

In summary, we demonstrated that Bi121 significantly inhibited various strains of SARS-CoV-2

in the two cell lines tested. This inhibition was also observed with the rVSV-ΔG-SARS-CoV-2 system that represents spike protein mutations of various SARS-CoV-2 lineages. Moreover, Bi121 (19).

Broad-spectrum antiviral against SARS-CoV-2 is a global need as new virus lineages with more immune-thwarting mutations are evolving (20). Bi121 has the potential to become a successful therapeutic because of the strong antiviral activity without cytotoxic effects and is a thermally stable compound without the need for special logistics support for distribution. This is particularly important for low-resource setting countries that doesn't have special transportation needs or logistics support. There is significant safety information (8-12) on use of Pelargonium-based actives for human respiratory applications that warrants a fast-track clinical development.

The nasal epithelium is where most respiratory viral infections, including SARS-CoV-2 infects (7) . Development of Bi121 in a nasal liquid dosage as a preventative treatment on nasal tissue may reduce virus. We are developing Bi121 as a therapeutic nasal spray for the first line of defense against SARS-CoV2 infection. We are currently testing its efficacy in the MA10 animal model, a SARS-CoV-2 in vivo model (21) and identifying antiviral molecular entities in B121 fractions using mass spectroscopy. 

Ongoing global and regional adaptive evolution of SARS-CoV-2

Evolutionary study of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emerging coronavirus: Phylogenetic analysis and literature review

Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies

Characteristics of SARS-CoV-2 and COVID-19

A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae)

Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children

EPsH 7630 (UmckaloaboH), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo

Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo H Phytomedicine

Effectiveness of Pelargonium sidoides in pediatric patients diagnosed with uncomplicated upper respiratory tract infection: a single-blind, randomized, placebo-controlled study

Investigation of the influence of EPs H7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses

The Root Extract of the Medicinal Plant Pelargonium sidoides Is a Potent HIV-1 Attachment Inhibitor

Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus

Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells

A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae)

Evolution patterns of SARS-CoV-2: Snapshot on its genome variants

Projected epidemiological consequences of the Omicron SARS-CoV-2 variant in England

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice